Twitter Facebook LinkedIn YouTube

Videos Tagged: zeeshan saeed

FSD Pharma awarded $2.81 Million from Dr. Raza Bokhari in an arbitration settlement
FSD Pharma awarded $2.81 Million from Dr. Raza Bokhari in an arbitration settlement 		Kevin Harrington, author, “Shark Tank” original and infomercial pioneer joins FSD Pharma’s Advisory Board
Kevin Harrington, author, “Shark Tank” original and infomercial pioneer joins FSD Pharma’s Advisory Board 		FSD Pharma receives No Objection Letter from Health Canada for Phase 1 clinical trial of LUCID-21-302 or Lucid-MS, for Multiple Sclerosis
FSD Pharma receives No Objection Letter from Health Canada for Phase 1 clinical trial of LUCID-21-302 or Lucid-MS, for Multiple Sclerosis
FSD Pharma submits its Clinical Trial Application for planned Phase-1 trial for Lucid-MS, a candidate for treatment of MS
FSD Pharma submits its Clinical Trial Application for planned Phase-1 trial for Lucid-MS, a candidate for treatment of MS 		FSD Pharma reports that the claim for USD $30.2 million brought by Dr. Raza Bokhari, the company’s former CEO, has been dismissed in its entirety
FSD Pharma reports that the claim for USD $30.2 million brought by Dr. Raza Bokhari, the company’s former CEO, has been dismissed in its entirety 		FSD Pharma, a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced the submission of an Investigational New Drug or “IND” application with the U.S. Food and Drug Administration and Health Canada.
FSD Pharma, a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced the submission of an Investigational New Drug or “IND” application with the U.S. Food and Drug Administration and Health Canada.
FSD Pharma, a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has closed the sale of non-core assets for $16.4 million.
FSD Pharma, a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has closed the sale of non-core assets for $16.4 million. 		FSD Pharma receives license to sell cannabis for medical purposes
FSD Pharma receives license to sell cannabis for medical purposes 		FSD Pharma signs non-binding LOI with Solarvest BioEnergy to develop and test pharma-grade cannabinoids from algae
FSD Pharma signs non-binding LOI with Solarvest BioEnergy to develop and test pharma-grade cannabinoids from algae
FSD Pharma’s cannabis facility in Ontario officially valuated at $105 million, forecast to hit $420 million after completion of 3 million Sq Ft expansion
FSD Pharma’s cannabis facility in Ontario officially valuated at $105 million, forecast to hit $420 million after completion of 3 million Sq Ft expansion 		FSD Pharma Inc. has appointed Rupert Haynes as Chief Executive Officer
FSD Pharma Inc. has appointed Rupert Haynes as Chief Executive Officer 		FSD Pharma, a licensed cannabis producer, adds high level government relations executive, David Urban to Board of Directors
FSD Pharma, a licensed cannabis producer, adds high level government relations executive, David Urban to Board of Directors
FSD Pharma signs binding letter of intent to acquire NASDAQ-listed Therapix Biosciences, a developer of cannabinoid-based treatments
FSD Pharma signs binding letter of intent to acquire NASDAQ-listed Therapix Biosciences, a developer of cannabinoid-based treatments 		FSD Pharma and SciCann Therapeutics Launch Clinical Cannabis-based Research Program in Israel
FSD Pharma and SciCann Therapeutics Launch Clinical Cannabis-based Research Program in Israel